Skip to main content
OpenTrials

Clinical trial condition

Recurrence

Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.

2,312 public trials 521 recruiting studies
Refine in advanced search Browse all conditions

Recurrence trial results

Completed

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

NCT02651662

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Johns Hopkins University Baltimore, Maryland, United States
  • Dana Farber/Harvard Cancer Center - PO box 849168 Boston, Massachusetts, United States
  • Harvard Medical School - Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Cancer & Hematology Centers of Western Michigan Grand Rapids, Michigan, United States
View all 30 locations
View Trial Details
Completed

A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:

NCT06676072

Conditions
Arrhythmias, Cardiac, Atrial Arrhythmia, Atrial Fibrillation, +9 more
Locations
  • HonorHealth Scottsdale, Arizona, United States
  • Arkansas Heart Hospital Little Rock, Arkansas, United States
  • Stanford University Medical Center Stanford, California, United States
  • South Denver Cardiology Associates PC Littleton, Colorado, United States
View all 32 locations
View Trial Details
Completed

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

NCT06113081

Conditions
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome, +17 more
Locations
  • Clinica di Ematologia - AOU Ospedali Riuniti delle Marche Ancona, Italy
  • S.C. Ematologia e Trapianto emopoietico - A.O. S.Giuseppe Moscati Avellino, Italy
  • Clinica Dermatologia - A.O.U. Policlinico Consorziale Bari, Italy
  • U.O.C. Ematologia - IRCCS Istituto Tumori Giovanni Paolo II Bari, Italy
View all 21 locations
View Trial Details
Completed

A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

NCT05144841

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0229) Orange, California, United States
  • Innovative Clinical Research Institute ( Site 0202) Whittier, California, United States
  • Georgetown University Medical Center ( Site 0204) Washington D.C., District of Columbia, United States
  • Northside Hospital ( Site 0206) Atlanta, Georgia, United States
View all 71 locations
View Trial Details
Completed

Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)

NCT01774630

Conditions
Bone Marrow Diseases, Chronic Disease, Disease Attributes, +11 more
Locations
  • CHU Angers Angers, France
  • Institut Bergonié Bordeaux, France
  • Centre Hospitalier de Versailles - Hôpital André Mignot - Service de Médecine B Le Chesnay, France
  • CHU de Nice, Service Hématologie Clinique Nice, France
View Trial Details

Related conditions